What's hot

View all perspectives
What's Hot

JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay

Watch video →

RheumNow Rheumatology Roundup: Drs. Kavanaugh and Cush

Rheumatology Roundup! Drs. Cush and Kavanaugh convene for their annual impromptu review of some of the best and more interesting abstracts presented at ACR 2021.    

Watch video →

TNF Inhibitor Panel Discussion: ACR21 Annual Meeting

RheumNow TNFi faculty convened to discuss several TNFi-related abstracts presented at ACR 21. Panelists: Drs. Aurelie Najm, Janet Pope, David Liew, Eric Dein and Swetha Alexander. 

Watch video →

Spondyloarthritis Panel Discussion: ACR21 Meeting

Panelists: Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood. Abstracts discussed include #0562, #1919, #0907, #0364 and #0919

Watch video →

Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay

Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting.

Watch video →

Diagnosing (Bad) VEXAS: The Experts Speak Drs. Beck and Ferrada

Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting.

Watch video →

Pediatric Psoriatic Arthritis: Dr. Eric Ruderman

Dr. Ruderman discusses abstracts #1424 presented at the ACR21 annual meeting.

Watch video →

Urine Proteome Advances: What Do They Mean? Dr. Michelle Petri

Dr. Petri reviews abstracts #1422 and #1936, presented at the ACR21 annual meeting.

Watch video →

ACR21 Day 3 Recap: Polypharmacy, New Lupus Drugs, VEXAS, Safety Data

Blurb: Drs. Jack Cush and the RheumNow Faculty Drs. Akhil Sood, Antoni Chan, Olga Petryna and Eric Dein, discuss highlights from Day 3 (Monday) at the ACR21 annual meeting. Abstracts include #1367, #1044, #1444, #1083 and more.

Watch video →

Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles

Dr. Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting.

Watch video →

Predictors of TNF Response with Drs. Pope, Dein and Liew

Drs. Janet Pope, David Liew and Eric Dein discuss TNF data presented at the ACR21 annual meeting, including abstracts #1251, #1442, #1448.

Watch video →

Caring for the Older Patient with Rheumatic Disease: Drs. Makris, Yung and Dao

Drs. Kathryn Dao, Una Makris and Raymond Yung discuss the field of geriatric rheumatology and caring for the older patient with rheumatic disease.

Watch video →

Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares

  Drs. Jack Cush, Yuz Yusof, Bella Mehta, Olga Petryna and Rachel Tate review autoinflammatory data presented at the ACR21 annual meeting, including abstracts #1100, #1062, #1426, #0252, #0195, and #1083.

Watch video →

FDA Session Review: Dr. Arthur Kavanaugh

Dr. Kavanaugh discussed the FDA session presented at the ACR21 annual meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.

Watch video →

The Respiratory Tract and RA with Drs. Sparks, McDermott and Kronzer

Drs. Jeffrey Sparks, Greg McDermott and Vanessa Kronzer discuss work in the area of respiratory disease in RA, mucosal paradigm, RA-ILD, bronchiectasis, as well as their experience as virtual attendees at the ACR21 annual meeting.

Watch video →

Pulmonary Hypertension in Adult Onset Still's Disease: Dr. Jack Cush

Dr. Cush reviews poster #1100 presented at the ACR21 annual meeting.

Watch video →

Data on Existing SLE Medications, Patient Centered Outcomes, and Exercise: Dr. Michelle Petri

Dr. Petri discusses data on existing SLE medications, patient-centered outcomes and the importance of exercise, presented Monday at the ACR21 annual meeting.

Watch video →

ACR21 Day 2 Recap: CV Risk, Tapering in SpA, Microbiome in PsA, Vit D

Drs. Jack Cush and the RheumNow Faculty Drs. David Liew, Swetha Ann Alexander, Meral El Ramahi, Mrinalini Dey and Robert Chao, discuss highlights from Day 2 (Sunday) at the ACR21 Virtual meeting.

Watch video →
      FDA Safety Update - Questions for Dr. Nikolov, Habal, Golding, Rajpal
      - Do we need post marketing RCTs BARI and UPA: one

      Dr. John Cush RheumNow

      4 years 1 month ago
      FDA Safety Update - Questions for Dr. Nikolov, Habal, Golding, Rajpal - Do we need post marketing RCTs BARI and UPA: one in prog for BARI, not for UPA - 1133, why high CI of 1.8? Based on stricter margins based on prior studies with diabetes - Are Tyk2 a worry? to early -#ACR21
      FDA Safety Update - Questions for Dr. Nikolov, Habal, Golding, Rajpal
      - Bari OK in COVID but now CV risk: theres a limit

      Dr. John Cush RheumNow

      4 years 1 month ago
      FDA Safety Update - Questions for Dr. Nikolov, Habal, Golding, Rajpal - Bari OK in COVID but now CV risk: theres a limit (14d) for Bari in COVID - CV Risk applied to all JAKi - largely because all have same indication, same populations at risk #ACR21
      FDA update - the safety of XIAFLEX injections (collagenase for Dupytrens) under review #ACR21 https://t.co/KOP3P8ASqN

      Dr. John Cush RheumNow

      4 years 1 month ago
      FDA update - the safety of XIAFLEX injections (collagenase for Dupytrens) under review #ACR21 https://t.co/KOP3P8ASqN
      RT @alicia_hinze: Excellent Rheum Pearls session w/ Drs. Kolfenbach & Stone:
      🔘⬆️CRP in SLE:: think infection

      Alicia Hinze alicia_hinze

      4 years 1 month ago
      Excellent Rheum Pearls session w/ Drs. Kolfenbach & Stone: 🔘⬆️CRP in SLE:: think infection not flare 🔘Ferritin:ESR ratio differentiate JIA flares from MAS 🔘Dilated capillaries at eyelid margin in JDM = disease activity 🔘Auscultate Back for bruits in TAK #ACR21 https://t.co/3pUOhYR3L2
      RT @DrPedsRheum: @jaymehtamd When to escalate #MISC Tx @jaymehtamd #PedsRheum #ACR21

      📌fever, cardiac dysfunction, ve

      Herman Tam DrPedsRheum

      4 years 1 month ago
      @jaymehtamd When to escalate #MISC Tx @jaymehtamd #PedsRheum #ACR21 📌fever, cardiac dysfunction, ventilatory support, altered mental status, MAS, organ-threatening 📌Anakinra vs Tocilizumab vs Infliximab 📌Anticoagulation https://t.co/jkQUWYaOkT
      FDA Update: FDA timeline for revision of the labels for TOFA, BARI, UPA - all needing to add a boxed warning on CV and

      Dr. John Cush RheumNow

      4 years 1 month ago
      FDA Update: FDA timeline for revision of the labels for TOFA, BARI, UPA - all needing to add a boxed warning on CV and cancer risk - This could take 2-3 mos- This is why youre still waiting.. #ACR21 https://t.co/DfJWWYuUQh
      FDA Safety Update on JAK Inhibitors - bottom line on the Tofactitinib Post-Marketing (PMR) study published Sept 1st (can

      Dr. John Cush RheumNow

      4 years 1 month ago
      FDA Safety Update on JAK Inhibitors - bottom line on the Tofactitinib Post-Marketing (PMR) study published Sept 1st (cancer higher rates of lung CA and lymphoma with both doses of Tofa vs TNFi) #ACR21 https://t.co/UGbiTGVpgW
      RT @uptoTate: GOSH and NAC pedi CAPS pts study since 2005: anti-IL1 treatment has major impact on prevention and tx of C

      Dr. Rachel Tate uptoTate

      4 years 1 month ago

      GOSH and NAC pedi CAPS pts study since 2005: anti-IL1 treatment has major impact on prevention and tx of CAPS symptoms. Observed by improved CAPS clinical dz activity scores; and normalized inflammatory markers. Abs 1110 #ACR21 #RheumNow @RheumNow https://t.co/xXrnVeRAq5

      RT @uptoTate: ASAS PerSpA study findings: rheumatologists tended to dx IBD-SpA in pts w peripheral arthritis more commo

      Dr. Rachel Tate uptoTate

      4 years 1 month ago
      ASAS PerSpA study findings: rheumatologists tended to dx IBD-SpA in pts w peripheral arthritis more commonly than axial symptoms. IBD predominantly presenting symptoms. Abs 1310 #ACR21 #RheumNow @RheumNow https://t.co/Gq1b5gXn0v https://t.co/oZRvwvgbJD
      RT @AkhilSoodMD: Abstr 1313
      Lee & Colleagues used clustering analysis to study impact of comorbidities in patients w

      Akhil Sood MD AkhilSoodMD

      4 years 1 month ago
      Abstr 1313 Lee & Colleagues used clustering analysis to study impact of comorbidities in patients with #axSpA - Comorbidities can influence treatment outcomes and should be accounted for in when treating #axSpA #ACR21 @RheumNow https://t.co/rN7LPQ9qEk
      RT @MeralElRamahiMD: Clinical Pearl from Dr. @JKolfenbach:
      ⭐️(-) ANCA doesn't r/o limited GPA
      ⭐️Biopsies can be

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 1 month ago
      Clinical Pearl from Dr. @JKolfenbach: ⭐️(-) ANCA doesn't r/o limited GPA ⭐️Biopsies can be just as important for ruling out mimics: ‣Neoplastic Dx (NK/T cell sinus lymphomas) ‣Histiocytic process ‣Infectious (fungal, mycobacteria) ‣Foreign material (cocaine) #ACR21 @RheumNow https://t.co/PEoYPBFLj0
      RT @Janetbirdope: #Precisionmedicine is here but we’re not using it? A 23 molecular signature response classifier (MS

      Janet Pope Janetbirdope

      4 years 1 month ago
      #Precisionmedicine is here but we’re not using it? A 23 molecular signature response classifier (MSRC) identified pts w RA unlikely to respond to #TNFi. no response was<ACR50 over 1yr. 175 w 26⬆️MSRC & 47 ⬆️⬆️MSRC. If ⬇️MSRC29%<ACR50 v 42&60%. ?cost Abst#1252 #ACR21 @RheumNow https://t.co/xdYyN0oXrh
      RT @DrPetryna: Abst1100 #ACR2021 @RheumNow PAH in AOSD rare, mostly in polycyclic disease, associated w/flares (85%). ov

      Olga Petryna DrPetryna

      4 years 1 month ago
      Abst1100 #ACR2021 @RheumNow PAH in AOSD rare, mostly in polycyclic disease, associated w/flares (85%). overall survival 93% at 1 year and 74% at 3 years. PAH was severe at diagnosis: 2 (15%), 7 (54%) and 4 (31%) patients were in NYHA functional class II, III and IV, respectively. https://t.co/x20LooA2G7
      RT @bella_mehta: Always thought⬆️health care access in Canada would lead to⬆️utilization of arthroplasty also ri

      Bella Mehta bella_mehta

      4 years 1 month ago
      Always thought⬆️health care access in Canada would lead to⬆️utilization of arthroplasty also rich-poor differences would be lower due to universal health access. Our study Canada Vs US and says otherwise!! Rich-poor differences are📈 greater in Canada! @rheumnow #abst1037 #ACR21 https://t.co/wKHXpsgSJn
      RT @uptoTate: While outcomes didn't worsen, de novo PsO can occur at any time point in axSpA (results per 6 year, DESIR

      Dr. Rachel Tate uptoTate

      4 years 1 month ago
      While outcomes didn't worsen, de novo PsO can occur at any time point in axSpA (results per 6 year, DESIR cohort study.) Regular follow ups are key to monitoring. Abs 1311 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/X1bot5UJ6Q https://t.co/qfbDhCT9q5

      Podcasts

      • Giant Cell Arteritis and Polymyalgia Rheumatic Wrapup: Drs. Calabrese, Liew, Conway and Mackie 00:20:18
      • Reproductive Health in Rheumatic Diseases: Drs. Bermas, Buyon and Dao 00:20:26
      • The Expert Gout Panel with Drs. Neogi, Saag, Pillinger, Cush and O'Dell 00:35:26

      Catch up on Conference Podcasts

      ×